SPOTLIGHT: Repligen touts positive data


Repligen announced positive results from a Phase II clinical trial to evaluate the use of RG1068, synthetic human secretin, as an agent to improve the assessment of pancreatic duct structures by magnetic resonance imaging. The study showed an improvement in sensitivity of detection of structural abnormalities of the pancreatic duct of approximately 20 percent with no loss in specificity, consistent with prior data and expectations. Release

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.